Loading…

Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors

A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in...

Full description

Saved in:
Bibliographic Details
Published in:Journal of computer-aided molecular design 2009-08, Vol.23 (8), p.555-569
Main Authors: Gozalbes, Rafael, Mosulén, Silvia, Carbajo, Rodrigo J., Pineda-Lucena, Antonio
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173
cites cdi_FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173
container_end_page 569
container_issue 8
container_start_page 555
container_title Journal of computer-aided molecular design
container_volume 23
creator Gozalbes, Rafael
Mosulén, Silvia
Carbajo, Rodrigo J.
Pineda-Lucena, Antonio
description A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in the dissemination of metastatic cancer cells. Several pharmacophore hypotheses were initially developed from the most active heparanase inhibitors known to date and, after their application to a pool of 27 known heparanase inhibitors and a database of 1,120 compounds approved by the FDA, a four-point pharmacophore model was selected as the most predictive. This model was subsequently applied to a database of 686 chemical fragments, and a subset of 100 fragments accomplishing completely or partially the four-point model was selected to perform nuclear magnetic resonance experiments to validate the hypothesis. The experimental studies confirmed the reliability of our pharmacophore model, its applicability to in silico databases in order to reduce the number of compounds to be experimentally screened, and the possibility of generating fragment libraries enriched in heparanase inhibitors.
doi_str_mv 10.1007/s10822-009-9269-0
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_36343327</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36343327</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi0EokPhAdggiwW7wPElzniJyqWVCkioC3aWk5xMXCV2OM5U6kPwzniYEZWQWNmWv__35WPspYC3AqB5lwVspawAbGWlsRU8YhtRN6rSthaP2QashMrU-scZe5bzLZSMNfCUnQmrpWgkbNivD3iHU1pmjCv3sedfv3znd34KvV9DijwNfA4xzH7iy-hp9l1axkTIx_slrSNmzHxIxMuU7zAi_Y0N5Hd_WqfQkqdQQIwUuhF7HiIfcfHko89YVmNow5ooP2dPBj9lfHEaz9nNp483F5fV9bfPVxfvr6tOGbtWQg5NebrZgpZdD3aQA4geVQ3gEZq6abVGJaGB3uitbqXdKm206rDvtGjUOXtzrF0o_dxjXt0ccofT5COmfXbKKK2UPICv_wFv055iuZqTwqjaGDAFEkeoo5Qz4eAWKh9G906AO3hyR0-ueHIHTw5K5tWpeN_O2D8kTmIKII9ALltxh_Rw8v9bfwN1ZZ8q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216356606</pqid></control><display><type>article</type><title>Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors</title><source>Springer Link</source><creator>Gozalbes, Rafael ; Mosulén, Silvia ; Carbajo, Rodrigo J. ; Pineda-Lucena, Antonio</creator><creatorcontrib>Gozalbes, Rafael ; Mosulén, Silvia ; Carbajo, Rodrigo J. ; Pineda-Lucena, Antonio</creatorcontrib><description>A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in the dissemination of metastatic cancer cells. Several pharmacophore hypotheses were initially developed from the most active heparanase inhibitors known to date and, after their application to a pool of 27 known heparanase inhibitors and a database of 1,120 compounds approved by the FDA, a four-point pharmacophore model was selected as the most predictive. This model was subsequently applied to a database of 686 chemical fragments, and a subset of 100 fragments accomplishing completely or partially the four-point model was selected to perform nuclear magnetic resonance experiments to validate the hypothesis. The experimental studies confirmed the reliability of our pharmacophore model, its applicability to in silico databases in order to reduce the number of compounds to be experimentally screened, and the possibility of generating fragment libraries enriched in heparanase inhibitors.</description><identifier>ISSN: 0920-654X</identifier><identifier>EISSN: 1573-4951</identifier><identifier>DOI: 10.1007/s10822-009-9269-0</identifier><identifier>PMID: 19421720</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Animal Anatomy ; Binding Sites ; Biotechnology ; Cancer ; Chemistry ; Chemistry and Materials Science ; Computer Applications in Chemistry ; Computer-Aided Design ; Drug Discovery ; Enzymes ; Glucuronidase - antagonists &amp; inhibitors ; Glucuronidase - chemistry ; Histology ; Humans ; Inhibitors ; Ligands ; Magnetic Resonance Spectroscopy ; Morphology ; NMR ; Nuclear magnetic resonance ; Pharmacology ; Physical Chemistry ; Protein Binding ; Protein Conformation ; Small Molecule Libraries - chemistry ; Small Molecule Libraries - therapeutic use ; Structure-Activity Relationship</subject><ispartof>Journal of computer-aided molecular design, 2009-08, Vol.23 (8), p.555-569</ispartof><rights>Springer Science+Business Media B.V. 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173</citedby><cites>FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19421720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gozalbes, Rafael</creatorcontrib><creatorcontrib>Mosulén, Silvia</creatorcontrib><creatorcontrib>Carbajo, Rodrigo J.</creatorcontrib><creatorcontrib>Pineda-Lucena, Antonio</creatorcontrib><title>Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors</title><title>Journal of computer-aided molecular design</title><addtitle>J Comput Aided Mol Des</addtitle><addtitle>J Comput Aided Mol Des</addtitle><description>A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in the dissemination of metastatic cancer cells. Several pharmacophore hypotheses were initially developed from the most active heparanase inhibitors known to date and, after their application to a pool of 27 known heparanase inhibitors and a database of 1,120 compounds approved by the FDA, a four-point pharmacophore model was selected as the most predictive. This model was subsequently applied to a database of 686 chemical fragments, and a subset of 100 fragments accomplishing completely or partially the four-point model was selected to perform nuclear magnetic resonance experiments to validate the hypothesis. The experimental studies confirmed the reliability of our pharmacophore model, its applicability to in silico databases in order to reduce the number of compounds to be experimentally screened, and the possibility of generating fragment libraries enriched in heparanase inhibitors.</description><subject>Animal Anatomy</subject><subject>Binding Sites</subject><subject>Biotechnology</subject><subject>Cancer</subject><subject>Chemistry</subject><subject>Chemistry and Materials Science</subject><subject>Computer Applications in Chemistry</subject><subject>Computer-Aided Design</subject><subject>Drug Discovery</subject><subject>Enzymes</subject><subject>Glucuronidase - antagonists &amp; inhibitors</subject><subject>Glucuronidase - chemistry</subject><subject>Histology</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Ligands</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Morphology</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Pharmacology</subject><subject>Physical Chemistry</subject><subject>Protein Binding</subject><subject>Protein Conformation</subject><subject>Small Molecule Libraries - chemistry</subject><subject>Small Molecule Libraries - therapeutic use</subject><subject>Structure-Activity Relationship</subject><issn>0920-654X</issn><issn>1573-4951</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp1kctu1DAUhi0EokPhAdggiwW7wPElzniJyqWVCkioC3aWk5xMXCV2OM5U6kPwzniYEZWQWNmWv__35WPspYC3AqB5lwVspawAbGWlsRU8YhtRN6rSthaP2QashMrU-scZe5bzLZSMNfCUnQmrpWgkbNivD3iHU1pmjCv3sedfv3znd34KvV9DijwNfA4xzH7iy-hp9l1axkTIx_slrSNmzHxIxMuU7zAi_Y0N5Hd_WqfQkqdQQIwUuhF7HiIfcfHko89YVmNow5ooP2dPBj9lfHEaz9nNp483F5fV9bfPVxfvr6tOGbtWQg5NebrZgpZdD3aQA4geVQ3gEZq6abVGJaGB3uitbqXdKm206rDvtGjUOXtzrF0o_dxjXt0ccofT5COmfXbKKK2UPICv_wFv055iuZqTwqjaGDAFEkeoo5Qz4eAWKh9G906AO3hyR0-ueHIHTw5K5tWpeN_O2D8kTmIKII9ALltxh_Rw8v9bfwN1ZZ8q</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Gozalbes, Rafael</creator><creator>Mosulén, Silvia</creator><creator>Carbajo, Rodrigo J.</creator><creator>Pineda-Lucena, Antonio</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7SC</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AL</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>BKSAR</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>JQ2</scope><scope>K7-</scope><scope>K9.</scope><scope>KB.</scope><scope>L7M</scope><scope>L~C</scope><scope>L~D</scope><scope>M0N</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>P5Z</scope><scope>P62</scope><scope>PCBAR</scope><scope>PDBOC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20090801</creationdate><title>Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors</title><author>Gozalbes, Rafael ; Mosulén, Silvia ; Carbajo, Rodrigo J. ; Pineda-Lucena, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animal Anatomy</topic><topic>Binding Sites</topic><topic>Biotechnology</topic><topic>Cancer</topic><topic>Chemistry</topic><topic>Chemistry and Materials Science</topic><topic>Computer Applications in Chemistry</topic><topic>Computer-Aided Design</topic><topic>Drug Discovery</topic><topic>Enzymes</topic><topic>Glucuronidase - antagonists &amp; inhibitors</topic><topic>Glucuronidase - chemistry</topic><topic>Histology</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Ligands</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Morphology</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Pharmacology</topic><topic>Physical Chemistry</topic><topic>Protein Binding</topic><topic>Protein Conformation</topic><topic>Small Molecule Libraries - chemistry</topic><topic>Small Molecule Libraries - therapeutic use</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gozalbes, Rafael</creatorcontrib><creatorcontrib>Mosulén, Silvia</creatorcontrib><creatorcontrib>Carbajo, Rodrigo J.</creatorcontrib><creatorcontrib>Pineda-Lucena, Antonio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Computer and Information Systems Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>Computing Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Earth, Atmospheric &amp; Aquatic Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Computer Science Collection</collection><collection>Computer Science Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>Computer and Information Systems Abstracts – Academic</collection><collection>Computer and Information Systems Abstracts Professional</collection><collection>Computing Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database (ProQuest)</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Earth, Atmospheric &amp; Aquatic Science Database</collection><collection>Materials Science Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of computer-aided molecular design</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gozalbes, Rafael</au><au>Mosulén, Silvia</au><au>Carbajo, Rodrigo J.</au><au>Pineda-Lucena, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors</atitle><jtitle>Journal of computer-aided molecular design</jtitle><stitle>J Comput Aided Mol Des</stitle><addtitle>J Comput Aided Mol Des</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>23</volume><issue>8</issue><spage>555</spage><epage>569</epage><pages>555-569</pages><issn>0920-654X</issn><eissn>1573-4951</eissn><abstract>A combined strategy based on the development of pharmacophore hypotheses and NMR approaches is reported for the identification of novel inhibitors of heparanase, a key enzyme involved in tumor metastasis through the remodeling of the subepithelial and subendothelial basement membranes, resulting in the dissemination of metastatic cancer cells. Several pharmacophore hypotheses were initially developed from the most active heparanase inhibitors known to date and, after their application to a pool of 27 known heparanase inhibitors and a database of 1,120 compounds approved by the FDA, a four-point pharmacophore model was selected as the most predictive. This model was subsequently applied to a database of 686 chemical fragments, and a subset of 100 fragments accomplishing completely or partially the four-point model was selected to perform nuclear magnetic resonance experiments to validate the hypothesis. The experimental studies confirmed the reliability of our pharmacophore model, its applicability to in silico databases in order to reduce the number of compounds to be experimentally screened, and the possibility of generating fragment libraries enriched in heparanase inhibitors.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>19421720</pmid><doi>10.1007/s10822-009-9269-0</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0920-654X
ispartof Journal of computer-aided molecular design, 2009-08, Vol.23 (8), p.555-569
issn 0920-654X
1573-4951
language eng
recordid cdi_proquest_miscellaneous_36343327
source Springer Link
subjects Animal Anatomy
Binding Sites
Biotechnology
Cancer
Chemistry
Chemistry and Materials Science
Computer Applications in Chemistry
Computer-Aided Design
Drug Discovery
Enzymes
Glucuronidase - antagonists & inhibitors
Glucuronidase - chemistry
Histology
Humans
Inhibitors
Ligands
Magnetic Resonance Spectroscopy
Morphology
NMR
Nuclear magnetic resonance
Pharmacology
Physical Chemistry
Protein Binding
Protein Conformation
Small Molecule Libraries - chemistry
Small Molecule Libraries - therapeutic use
Structure-Activity Relationship
title Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A31%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20NMR%20validation%20of%20minimal%20pharmacophore%20hypotheses%20for%20the%20generation%20of%20fragment%20libraries%20enriched%20in%20heparanase%20inhibitors&rft.jtitle=Journal%20of%20computer-aided%20molecular%20design&rft.au=Gozalbes,%20Rafael&rft.date=2009-08-01&rft.volume=23&rft.issue=8&rft.spage=555&rft.epage=569&rft.pages=555-569&rft.issn=0920-654X&rft.eissn=1573-4951&rft_id=info:doi/10.1007/s10822-009-9269-0&rft_dat=%3Cproquest_cross%3E36343327%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-12f710868042cd09f2f01de3500ae0757b44e32070d6484b29834643cedc4173%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=216356606&rft_id=info:pmid/19421720&rfr_iscdi=true